Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

Artrya’s Growth Outlook Faces Pressure from Ongoing Losses

Sep 20, 2026 | Team Kalkine
Artrya’s Growth Outlook Faces Pressure from Ongoing Losses
Image source: shutterstock

  • AYA:ASX
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (AU$)

This report is an updated version of the report published on 21 September 2026 at 11:43 AM AEST.

Artrya Limited (ASX: AYA)

Artrya Limited (ASX: AYA) is an Australian medical-technology firm developing AI-powered software to detect, diagnose and manage coronary artery disease. Its flagship product, “Salix”, uses deep learning to analyse coronary CT angiography scans, helping physicians identify plaque, assess risk and streamline workflow.


Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…